MiMedx Group announced the publication of a peer reviewed study characterizing a potential mechanism by which placental-based allografts modulate the occurrence of scarring and fibrosis in surgical procedures. “We are pleased to have this study published in Nature – Scientific Reports, a leading, peer-reviewed journal with a reputation for publishing best-in-class scientific literature,” stated Michelle Massee, MIMEDX Vice President of R&D. “In addition to developing market-leading products, our aim is to continue to generate the industry’s most comprehensive library of clinical and scientific publications in support of our products’ use and efficacy. Through our research we hope to identify additional potential applications for amniotic membranes to improve patient outcomes. With the industry as a whole placing greater importance on generating robust clinical data in the field of skin substitutes, we believe that the addition of this study reaffirms our commitment to lead this field with innovation based on science and clinical evidence.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG:
- MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature – Scientific Reports
- MIMEDX to Host Second Quarter 2024 Operating and Financial Results Conference Call on July 31
- MiMedx initiated with an Overweight at Cantor Fitzgerald
- MIMEDX Announces the Appointment of Kim Moller to Chief Commercial Officer
- MiMedx names Kim Moller Chief Commercial Officer